Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | HEPA 1-6; Hepa-1-6; Hepa1-6 |
| Species | Mouse- C57L |
| Cat.No | ABC-TC077S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Liver |
| Disease | Hepatoma |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Liver Cancer Cell Lines |
Hepa 1-6 is a murine hepatoma cell line originally derived from liver tumor tissue of a male C57L/J mouse. The cells exhibit epithelial-like morphology with polygonal shapes and adherent culture properties. The karyotype of Hepa 1-6 is aneuploid, with a modal chromosome number ranging from 54 to 56. Functionally, Hepa 1-6 retain several hepatocyte-like features, including the expressing albumin, alpha-fetoprotein (AFP), and cytochrome P450 enzymes. However, they express low levels of hepatitis B virus (HBV) surface antigen compared to other hepatoma models. The unique feature of Hepa1-6 is its inability to integrate murine retroviruses or exogenous viral genomes. Moreover, Hepa 1-6 is tumorigenic in syngeneic or SCID mice.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The Hepa 1-6 cell line serves as a robust murine model for the study of hepatocellular carcinoma (HCC), offering a valuable resource for cancer research. It is particularly suited for establishing tumor modesl within immunocompetent mice, providing a physiologically relevant system for evaluating immune responses in controlled setting. Due to its compatibility with the host immune system, Hepa 1-6 is widely used in preclinical immuno-oncology studies, thereby expediting the exploration of diverse immunotherapy modalities, either as monotherapies or in combination with radiation, small molecular agents, and optimization of cancer immunotherapeutics under conditions that closely mimic the clinical environment.
